<DOC>
	<DOCNO>NCT00455689</DOCNO>
	<brief_summary>The purpose study examine impact hot flush sleep , mood , well-being . Hot flush ( `` hot flash '' ) feeling overheat , often follow heavy sweating , skin become red hot , discomfort . Sometimes hot flush follow chill . Some woman experience rapid heart rate . Hot flush happen night call night sweat , may interfere sleep . The investigator cause hot flush give study participant hormone medication call leuprolide ( Lupron ) . Hormones chemical naturally produce body . Leuprolide manufacture ( artificial ) hormone make body think reach menopause temporarily . Most woman begin hot flush within 4 week take leuprolide . The investigator also evaluate change sleep , mood , feeling well-being course study . The investigator use questionnaires measure change .</brief_summary>
	<brief_title>Understanding Experimentally Induced Hot Flushes</brief_title>
	<detailed_description>Hot flush common peri/postmenopausal woman woman receive breast cancer therapy . Every year United States , 1.3 million woman expect reach menopause . ( 1 , 2 ) Hot flush occur &gt; 85 % menopausal woman , typically persist several year . ( 3 ) In addition , 200,000 woman diagnose breast cancer US year . ( 4 ) Hot flush common side effect anti-estrogen therapy use treat estrogen-receptor positive ( ER+ ) breast cancer . Widely use anti-estrogen therapy use continuously many year , include tamoxifen , aromatase inhibitor ( AI ) , gonadotropin-releasing hormone ( GnRH ) agonists . ( 5 ) Hot flush persist ongoing use cancer treatment . ( 6 ) The number woman hot flush increase many woman decline estrogen therapy since result Women 's Health Initiative publish anti-estrogen therapy use widely longer period time woman breast cancer . ( 7 ) Hot flush impair quality-of-life produce discomfort , disrupt sleep , diminish mood , reduce overall well-being menopausal woman breast cancer patient . ( 5 , 8 ) They primary reason discontinuation anti-estrogen therapy . ( 9 ) Recent advance identify non-hormonal therapy hot flush ( e.g. , serotonergic agent gabapentin ) , ( 8 , 10-16 ) agent effective 60 % woman hot flush . ( 8 ) Better therapy need . Current study limit reliance population hot flush vary frequency intensity , bias perception influence self-reporting hot flush , ( 17 ) 30 % placebo-response rate . ( 8 , 18 ) Utilizing experimental model induce hot flush advance discovery novel hot flush therapy use robust reproducible system test potential therapy . An experimental model also permit great understanding effect novel therapy hot flush hot flush sleep , mood , quality-of-life . This work accelerate development effective therapy prevent alleviate hot flush , thereby improve adherence anti-estrogen therapy woman breast cancer quality-of-life woman hot flush . Etiology hot flush : Withdrawal estrogen central pathophysiology hot flush , ( 18 ) estrogen possibly exert effect hot flush hypothalamic thermoregulatory center . ( 18 ) Evidence support estrogen 's role derive woman hot flush occur spontaneously iatrogenically . Hot flush cause oöphorectomy GnRH agonist , lead rapid estrogen withdrawal , ( 19 ) SERMs ( e.g. , tamoxifen ) , antagonize estrogen receptor , ( 5 ) AI , block peripheral conversion androstenedione estrone , ( 20 , 21 ) primary estrogen source postmenopausal woman . ( 22 ) GnRH agonist : GnRH agonists leuprolide effective treatment premenopausal breast cancer prostate cancer men , also use woman endometriosis , fibroid , infertility . ( 23-27 ) On GnRH agonist therapy , hot flush develop within first 2-3 week treatment present least 80 % woman 4 week use . ( 19 , 28-31 ) An average 1 6 hot flush per day occur GnRH agonist therapy , may continue 3 month discontinuation . ( 19 , 28-31 ) GnRH agonists initially stimulate release gonadal steroid ( estradiol [ E2 ] , estrone [ E1 ] , leutinizing hormone [ LH ] , follicle-stimulating hormone [ FSH ] ) suppress secretion within 1-2 week treatment . ( 19 , 30 , 32 ) E2 E1 suppress level see oöphorectomy , like LH , remain persistently suppress , FSH rise 4 week ongoing GnRH agonist therapy . ( 19 , 30 , 32 ) Osteopenia see GnRH agonist use 6 month . ( 33 ) Impact hot flush sleep , mood , quality-of-life : Sleep disruption common strongly associate hot flush peri/postmenopausal woman ( 3 , 34 , 35 ) breast cancer patient . ( 5 , 36 ) Hot flush occur night ( night sweat ) lead repeat , brief awakening , abnormal sleep architecture , poor sleep quality . ( 37-39 ) Depression symptom occur 10 % perimenopausal woman . ( 40 ) Depression symptom peri/postmenopausal woman strongly link hot flush . ( 41 , 42 ) Impairment sleep , mood , quality-of-life also see GnRH agonist AI . ( 43-46 ) However , know whether sleep mood problem occur GnRH agonist AI cause hot flush consequence estrogen withdrawal . Neuro-anatomical correlate hot flush : Hot flush think induced change estrogen disrupt thermoregulatory region hypothalamus estrogen input hypothalamus . ( 3 , 18 ) Other evidence suggest change insular cortex correlate hot flush . ( 48 ) However , change hypothalamic insular region occur woman GnRH agonist-induced hot flush extensively investigate . Only one publish study date utilized functional neuro-imaging examine neuroanatomic correlate hot flush . ( 48 ) Using functional MRI testing , study find activation insular cortex hypothalamus individual hot flush event . Our study utilize PET technology explore hypothalamic insular change occur woman develop hot flush leuprolide . PET Imaging CNS : Dr. Hall , one co-investigators , use PET scan technique examine change hypothalamic activity estrogen infusion study . Her work show estrogen negative feedback occur hypothalamus inferior thalamus . ( 49 ) These data collect collaboration 2 co-investigators project , Drs . Dougherty Fischman , demonstrate PET scan use detect change hypothalamic activity occur serum level estrogen alter . The current study use similar PET scan method . Of neuroimaging method currently available , PET offer best combination resolution , sensitivity , ability study subcortical midline structure hypothalamus , range feasible experimental design , well-validated analytical tool . Early study document change regional cerebral blood flow presence estrogen . ( 50 ) Previous cross-sectional study use FDG PET demonstrate significant effect estrogen administration brain region associate memory sensitive cognitive change normal age Alzheimer 's Disease . ( 51-53 ) [ 18F ] 2-fluoro-2-deoxy-D-glucose ( 18FDG ) also use successfully measure change local cerebral glucose utilization rate elicit pharmaceutical cognitive challenge . ( 54 ) As native glucose , FDG transport brain across capillary endothelium cell membrane facilitate diffusion phosphorylated FDG-PO4 . However , FDG-PO4 undergo metabolism cerebral activity glucose-6-phosphatase low , cause significant dephosphorylation . Thus , intravenous injection , local cerebral concentration FDG rise plateau level directly proportional glucose utilization rate .</detailed_description>
	<mesh_term>Hot Flashes</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Women 1845 year old Premenopausal , define regular month menstrual cycle ( every 2535days ) past 6 month corroborate midluteal phase progesterone &gt; 3 ng/ml Willingness use barrier method contraception study completion study menses resume Good general health normal hemoglobin , prolactin , TSH , liver function test ( SGOT , SGPT , bilirubin ) renal function test ( BUN , creatinine , alkaline phosphatase ) Pregnancy , confirm serum HCG screen visit also additional serum HCG test conduct 3rd visit GnRH agonist give 24 hour prior PET scan . Breastfeeding Hot flush , determine skinconductance monitor measurement hot flush diary obtain screen visit initiation study medication Hemoglobin screen visit le 10 gm/dL Abnormal liver function test ( SGOT , SGPT , bilirubin &gt; 2.5 time upper limit normal ) Abnormal renal function test ( BUN creatinine &gt; 2 time upper limit normal ) BMI &gt; 35 kg/m2 Previously diagnose osteoporosis osteopenia Psychiatric disorder involve mood ( current major depression , current dysthymia , bipolar disorder ) anxiety ( current panic disorder , current obsessive compulsive disorder ) , psychotic disorder , current anorexia nervosa , current alcohol substanceuse disorder , determine administration Patient Health Questionnaire ( PHQ ) score &gt; 16 MontgomeryÅsberg Depression Rating Scale ( MADRS ) indicate significant depression symptom screen study visit . If PHQ suggest one psychiatric disorder , Structured Clinical Interview DiagnosisIV ( SCID ) 48 administered ensure potential study participant one psychiatric disorder . Previous severe depression , characterize psychotic symptom inpatient psychiatric hospitalization suicide attempt 5 year prior study enrollment Previous severe depression , characterize psychotic symptom inpatient psychiatric hospitalization suicide attempt 5 year prior study enrollment Evidence suicidal homicidal ideation , determine PHQ MADRS screen visit Sleep apnea , narcolepsy , diagnose sleep disorder , determine clinical interview conjunction Sleep Disorders Questionnaire ( 55 , 56 ) administer screen visit Contraindication , hypersensitivity , previous allergic reaction GnRH agonists Regular use centrally active medication ( antidepressant , anxiolytic , hypnotic , anticonvulsant ) least one month Use hormonal medication least 2 month Use ketoconazole , clomiphene citrate , anabolic/androgenic steroid precede 3 month Renal insufficiency Abnormal vaginal bleeding History thromboembolism cardiovascular disease History congestive heart failure condition require sodium restriction History spinal cord compression Metastatic vertebral lesion Memory disorder Urinary tract obstruction History liver , kidney , pulmonary , metabolic disease may put subject risk treat study medication . Contraindication PET MRI imaging , cardiac pacemaker , implanted cardiac defibrillator , brain aneurysm clip , cochlear implant , ocular foreign body , shrapnel and/or prior history allergic reaction dye use scan .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>April 2012</verification_date>
	<keyword>Lupron</keyword>
	<keyword>Premenopausal</keyword>
	<keyword>Hot flash</keyword>
	<keyword>PET</keyword>
	<keyword>MRI</keyword>
</DOC>